Sign up to our newsletter Subscribe
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Sign up to our newsletter Subscribe
The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.
An error has occurred, please try again later.